FDA Marketing Authorization Decision on Early Stage-Low Risk Breast Cancer Expected in Q1 2025 Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel, Nov. 26, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"),...
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation
Seaking AlphaSeeking Alpha / Seaking Alpha 3 hours ago 1 Views
Comments